Trial Profile
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (Randomized Pilot Study Utilizing Ivacaftor for the Treatment of Refractory Gram-Negative Bacterial CRS)
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 22 May 2022
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- 16 May 2022 Planned primary completion date changed from 1 May 2022 to 31 Dec 2023.
- 17 Jun 2021 Planned End Date changed from 1 May 2022 to 1 May 2024.
- 17 Jun 2021 Planned primary completion date changed from 1 May 2021 to 1 May 2022.